RT Journal Article
SR Electronic
T1 Identification of atypical circulating tumor cells with prognostic value in metastatic breast cancer patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.29.20203653
DO 10.1101/2020.09.29.20203653
A1 Alexia Lopresti
A1 Laurys Boudin
A1 Pascal Finetti
A1 Séverine Garnier
A1 Anaïs Aulas
A1 Maria-Lucia Liberatoscioli
A1 Olivier Cabaud
A1 Arnaud Guille
A1 Alexandre de Nonneville
A1 Quentin Dacosta
A1 Emilie Denicolai
A1 Jihane Pakradouni
A1 Anthony Goncalves
A1 Daniel Birnbaum
A1 Claire Acquaviva
A1 François Bertucci
A1 Emilie Mamessier
YR 2021
UL http://medrxiv.org/content/early/2021/10/05/2020.09.29.20203653.abstract
AB Background Circulating tumor cells (CTCs) have a strong potential as a quasi-non-invasive tool to set up precision medicine strategy for cancer patients. Tremendous efforts have been made to develop the second-generation of “filtration-based” technologies to detect CTCs, revealing a surprising heterogeneity among those cells. Here, we performed the largest and simultaneous analysis of all atypical circulating tumor cells (aCTCs) detected with a filtration-based technology, in a cohort of metastatic breast cancer (mBC) patients, and correlated their presence with clinicopathological and survival data.Methods The PERMED-01 study enrolled patients with mBC refractory to systemic therapy. We prospectively analyzed aCTCs present at the time of inclusion in the study, using the Screencell®Cyto device (n=91). Subsets cut-offs were established and evaluated for correlation with clinicopathological data, including progression-free survival (PFS) and overall survival (OS).Results The median number of aCTCs found in mBC was 8.3 per mL of blood. Three subsets of aCTCs, absent from controls, were observed in mBC patients: single (s-aCTCs), circulating tumor micro-emboli (CTM), and giant-aCTCs (g-aCTCs). The presence of g-aCTCs was associated with shorter PFS and OS in multivariate analyses. For 23 cases, the analysis was completed with advanced immunofluorescence staining and showed that CTM and g-aCTCs displayed a hybrid phenotype for epithelial and mesenchymal markers.Conclusions This study highlights the heterogeneity of aCTCs in mBC patients both at the cytomorphological and molecular levels when using a Screencell®Cyto device. It reveals the g-aCTC subset as a prognostic factor and a potential stratification tool that might help to orientate late-stage mBC patients’ therapeutic care.Competing Interest StatementAG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.Clinical TrialNCT02342158Funding StatementThis work has been supported by Inserm, Institut Paoli-Calmettes (SIRIC INCa-DGOS-Inserm 6038), and grants from the Ligue Nationale Contre Le Cancer (EL2016.LNCC/DaB, EL2019.LNCC/FB), Association Ruban Rose, and Foundation Groupe EDF. AL was supported by the fellowship DOC4 from the Fondation ARC (DOC20180507420). AA was supported by a postdoctoral fellowship from the Fondation ARC (PDF20180507565) and the Fondation de France (00107936). Conflict of Interest: AG received non-financial support from Astra Zeneca, Novartis, Pfizer, Roche.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National ethics committee (CPP Sud-Mediterranee) registered as identifier NCT02342158 at the ClinicalTrials.gov platformAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on requestaCTCsatypical Circulating Tumor CellsCAMLsCancer-Associated Macrophage-Like cellsCTCsCirculating Tumor CellsCTMCirculating tumor micro-emboliE/M statusEpithelial to Mesenchymal statusEMTEpithelial to Mesenchymal Transitiong-aCTCgiant-atypical Circulating Tumor CellsGMMGaussian finite Mixture ModelLRLikelihood RatiomBCmetastatic breast cancerMGGMay Grünwald GiemsaN/CnucleocytoplasmicOSOverall survivalPBSPhosphate Buffered SalinePFSProgression free survivalRTroom temperatures-aCTCsingle-atypical Circulating Tumor CellsTAMTumor Associated MacrophageTNTriple Negative